Member Info for Wigwammer

If there is a message for investors from this government policy and the constructive rhetoric from related medical organisations in recent weeks, it is that they sense a sea change may be coming, and they want to appear prescient and on the front foot. GLA

“Recruitment is going superbly well? people are loving this trial..? presumably on the basis that that the specialists are liking what they hear. The point that the monotherapy cohorts are filling faster than the keytruda combination, may also indicate the enthusiasm amongst specialists to find an alternative to PD inhibitors.

Thanks again for the recording Botski, and one comment you made which went a bit unnoticed was this.. “ Ottenmeiser once told LD he thought they were going to win a Nobel prize. “…. He might well know a thing or two:

Director of Clinical Research, The Clatterbridge Cancer Centre
Professor of Immuno-Oncology, University of Liverpool
Visiting Professor, University of Southampton
Adjunct Professor, La Jolla Institute for Immunology, La Jolla, California, USA
European Society of Medical Oncology
Fellow of the Royal College of Physicians
American Society of Clinical Oncology
Cancer Immunotherapy Collaborative (Germany)
CIMT Immunoguiding Program steering group (European Collaborative)
European Academy for Tumor Immunology (EATI)
National Cancer Research Clinical Trials Melanoma Group
Editorial Roles:

Cancer Immunology, Immunotherapy
Journal of Immunotherapy of Cancer
Immunotherapy Advances

LOL 2CVguy .. :)

From an investors pov, two key things have advanced re funding. 1) LD has explicitly stated BioNTech are “even more interested” in Moditope than TCR - first time they have been explicitly linked. 2) BioNTech’s cash position has moved from $2.5bn to $13.6bn in the space of a year. We know anyway the links between the two, because they worked together closely on the Grand Challenge. So if the moditope data keeps coming in as hoped, we now know they have at least one believer, and crucially that believer now has very deep pockets. ATB

“It will be the flip side. If this really is working there will be huge enthusiasm. We’ve had to go longer and deeper but when we get there it will be a bigger story because we will have achieved what nobody else has achieved…. a lot of people in this room are waiting for that moment to go out and shout about it, it’s just a little bit too soon.” GLA :)

BioNTech currently has $13.6bn cash on the balance sheet. So capable of paying an attractive upfront :)

Things that stand out:
1. LD sounds like she is only falling more in love with moditope, and she will know more about the data than we do. New description of the DTH responses as “lovely”.
2. BionTech more interested in the vaccine, than TCR
3. LD thinks she may have the “ holy grail of cancer antibodies “

For balance - those expecting a double digit upfront from Genmab likely to be disappointed. Cash runway still to Q124.

Can only repeat what others have said - thank you very much botski. Look forward to listening :)

“ the Company's Annual General Meeting ("AGM") will take place on Monday 21 November 2022 at 14:00 GMT”

A bit of perspective. Genmab have likely just spent less than 1% of their net cash on the Scancell mab. I don’t think we are gonna be featuring much in the chats, though I’d like to be proven wrong..

Judging by the reaction here, it appears to have generated more questions than answers.

Seems like a strange thing to RNS. Not price sensitive and so a non regulatory disclosure might have been more appropriate.

As mentioned by bermuda and others, calculus appear to be selling. I imagine in the current environment they will be wary that many of their less well funded company investments may come calling for cash faster and in higher quantity than originally hoped ie calculus need liquidity. This would explain the muted reaction to an RNS which, as others have attested, is about as good as could be hoped at this stage. I’ve added.

Thanks raypointer. Interesting stuff. So many positive angles to the story :)

It’s an interesting point crumbs and I’m pleased with the RNS today. My guess is max $3m upfront. I’ve seen those big future milestone numbers too many times to take it too seriously. As another poster suggested however, it may encourage others to follow. ATB

I’m pretty sure if sclp got $54m upfront then it would be in the RNS. Why wouldn’t they show it? Our tech is amazing with big upfront value etc..The world is awash with big sounding deals with limited upfront, that ultimately dissolve to nothing, as I’m sure the likes of bermuda will attest. I own over 1m shares, but would like to know the upfront before claiming this is cracking news. Good news yes, but not cracking.

??? Well of course the fund/assets will be used to pay the pensioners each year. What else do you think it is there for? The assets will fall each year due to the pension payout, and the corresponding liability will also fall.

I think 68p was hit because Carclo came to be seen as a covid play, with punters buying into the dream that abundant tests and injectables would be needed. When that froth dissipated, so did the short term punters. But any investor who believes now the current fundamentals justify a 68p+ valuation - and that the obstacle is simply lack of communication - should be buying the stock in droves IMO. If that sort of premium can be justified then very often the market will find a way of realising it, even if current management cannot. My own belief is that this management team will get there, and I’m happy trusting my investment with them.

With respect cherryhiller, I couldn’t disagree more. I think the new management team have done a great job growing the business out of the ashes of the wipac problems, solidifying the financial position with both the banks and trustees, and communicating the story to shareholders. The 68p price you refer to is rather selective. Carclo was also trading at 4p in recent years when the market gave it little chance of surviving. Not only has it strongly recovered from those levels but I suspect the future for holders will be a glowing one, in large part thanks to management action. ATB